semaglutide fda approval history Wegovy (semaglutide) Rybelsus (semaglutide) FDA Approval History

Rybelsus should be used when prescribed for its intended purpose of managing type 2 diabetes

One RCT found that exenatide significantly reduced drinking in individuals with AUD and obesity, but not in those without metabolic comorbidities (Klausen MK et al, JCI Insight 2022;7(19):e159863)

Why These Medications May Increase Tendon Injury Risk The exact biological mechanism hasnt been established yet

A patient carrying a particular GLP1R variant might experience robust appetite suppression at microdose levels, while another individual with a different genetic profile may require standard dosing for the same effect

Clinical trials of semaglutide for weight loss (STEP 14) demonstrated average weight reductions of 1022% over 68 weeks, with many patients losing 20+ pounds and improving metabolic markers like blood pressure and blood sugar